Highmont Advisors

Highmont Advisors are company transition and growth experts with operational industry experience and access to turn-around capital.

[Highmont Advisors @HighmontAdvs]

The US FDA has approved #LabGrownMeat for the first time.

And so begins yet another paradigm- shifting industrial revolution within this generation to add to #AI, #supplychain, #cellandgene #advancedtherapies, etc.
https://t.co/VF3pUt3Zkg

#biomanufacturing #cellculture

[Alex Iskold | 2048.vc @alexiskold]

📚Blog Post: How a seed-stage company can run a simple and effective board meeting

https://t.co/rIcH4B9uQ1

@2048vc // #startuphacks // #VC

[Highmont Advisors @HighmontAdvs]

The Canadian #advancedtherapies biotechnology sector is having a moment so far in 2023. @SernovaCorp @aspectbiosys @CCRM_ca @BlueRockTx

[Lee Buckler @celltherapy]

Somehow I missed this one. @SernovaCorp announces a preclinical research collaboration with AstraZeneca to evaluate $SVA's novel Cell Pouch System™ for use in combination with AstraZeneca’s novel therapeutic cells. #celltherapy https://t.co/mb4hgxoiL2

[Highmont Advisors @HighmontAdvs]

@alexiskold Me too. No invite so I added myself to the waitlist this morning.

[Highmont Advisors @HighmontAdvs]

#synbio #bioengineering #bioagriculture #bioengineering #bioeconomy

[Highmont Advisors @HighmontAdvs]

We love this #RNAi, #ESG, and #foodsecurity co with hardcore science and recent product launches in the F&B market with global partners. Now they've pivoted to biotech using RNA to replace chemical pesticides, antibiotics and drugs.
https://t.co/gP0jVvA5XB

[Lee Buckler @celltherapy]

If I were to give any single piece of advice to anyone under 30 it is that the investment in building and maintaining a network of people early in one's career pays off like compound interest to future you for the rest of your life.

[Lee Buckler @celltherapy]

A European Perspective on Advanced Therapies Development: the needs, the challenges, the opportunities. An Interview with @HighmontAdvs Emmanuel Grillot.
https://t.co/OEYb6nqInn

[Highmont Advisors @HighmontAdvs]

The clinical-stage biopharmaceutical company @codiakbio, pioneering the development of exosome-based therapeutics, voluntarily files for Chapter 11 bankruptcy and will attempt to find a buyer for the whole business or its core assets. https://t.co/GoxTwXiGYl

[Lee Buckler @celltherapy]

The once-hot SPAC has certainly cooled in the last 12 months but NK cells are one of the next hot things in #celltherapy so I guess it makes sense that on the heels of the @coeptistx SPAC go-public in Oct, @NKGenBiotech does a SPAC go-public this week https://t.co/yvkg4l7Qzv

[Highmont Advisors @HighmontAdvs]

Despite a restructuring last year and putting on a brave face in light of a recent patient death, #celltherapy company @AthenexOncology is reported to have disclosed it is exploring a “broader range of strategic alternatives.”
https://t.co/0zlppXNGmb

[Highmont Advisors @HighmontAdvs]

Biotech and #celltherapy company, Sorrento Therapeutics, receives court approval for $75M DIP financing to fund continued operations during its bankruptcy process which was filed to protects its >$1B in assets in the face of creditor litigation.
https://t.co/dff0X0WTci

[Highmont Advisors @HighmontAdvs]

This.

[Alex Iskold | 2048.vc @alexiskold]

I invested in over 170 startups over the last 10 years.

I remember:

- every single startup.
- every single founder.
- every single round - how it went, who led, the price.

VC isn’t just about picking and checks.

Remembering and staying involved is a big part of the job!

[Highmont Advisors @HighmontAdvs]

"Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan" https://t.co/jks1Cs7qFH

[Highmont Advisors @HighmontAdvs]

...and another: "Bellicum halts trials after serious adverse event, looks for 'strategic alternatives" https://t.co/IuXRXGeEEQ

[Highmont Advisors @HighmontAdvs]

But one example: "Magenta issues dreaded ‘exploring strategic alternatives’ release after MGTA-117 failure". https://t.co/W5hvz9y0o9

[Highmont Advisors @HighmontAdvs]

Couldn't agree more! In addition to our growth strategy work, we are busy ramping up our #biotech #lifesciences turnaround team for projects across North America. If you love intense, short-term, deeply embedded, disruptive value creation, let's talk.

[Lee Buckler @celltherapy]

Suddenly (not surprisingly) seeing a relative explosion of #cellandgene #advancedtherapy #biotech companies pursuing 'strategic alternatives' in the face of the impending financial wall straight ahead. These transition cycles are the opportunity co's like @HighmontAdvs live for.

[Highmont Advisors @HighmontAdvs]

@physorg_com It may be interesting for readers to note that a strain of acrylamide-reducing yeast has already been developed by Renaissance Biosciences and commercialized by @WeAreKerry

https://t.co/6jZixIX0IG

[Highmont Advisors @HighmontAdvs]

@physorg_com It may be interesting for readers to note that a strain of acrylamide-reducing yeast has already been developed by Renaissance Biosciences and commercialized by @WeAreKerry

https://t.co/6jZixIX0IG

[Highmont Advisors @HighmontAdvs]

@AlphaNorthAsset While we understand it has been a disappointing private stock for many Canadian smallcap investors to-date we believe Renaissance Bioscience has made an important pivot with its #bioagriculture product pipeline, its growing commercial revenue, and will be a story to watch in 2023